Loading
Total declarations
Companies
▲ Purchases (6 ops.)
▼ Sales (0 ops.)
Latest filing published 04 Sept 2025 for Protalix BioTherapeutics, Inc..
Filing timeline
BuySaleAharon Schwartz
Insider track record
Disclosed buys
6
Disclosed sells
0
Signal history
Closed purchases
Market purchases
6
Positive at T+90
67%
Median T+90
+32.3%
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +46.6%Entry US$1.61 · Close at T+365 US$2.36
- +17.0%Entry US$1.53 · Close at T+365 US$1.79
- +71.0%Entry US$3.55 · Close at T+365 US$6.07
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Aharon Schwartz: trading record in brief
Aharon Schwartz is a declared insider at 2 companies; the most frequent names are Foamix Pharmaceuticals Ltd. and Protalix BioTherapeutics, Inc. In total, 8 filings cover trades dated from 26 November 2018 to 3 September 2025.
No open-market sale appears; the market trades are 6 purchases worth €855k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant. Since January 2025: 1 purchase and no sales on the market.
In size, the median ticket on the buying side is €159k. No cluster: in 6 purchases, no other insider of the company bought within 30 days. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 67% of cases, with a median move of +32.3%. This is a record of the past, not a forecast.
Most recently, on 4 September 2025, the filings show a share grant in Protalix BioTherapeutics, Inc. The clock since the last published purchase (12 August 2025) now reads 437 days. The median gap between a trade and its publication by SEC (Form 4) is 7 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Aharon Schwartz
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
7,500 sharesCommon StockSEC:0001415889-25-023704:0
129,000 shares@ US$1.59655.2% of flowCommon StockSEC:0001415889-25-021494:0
Canonical exit: 8 Sept 2025 (T+90)
110,000 shares@ US$1.416544.8% of flowCommon StockSEC:0001104659-23-001495:0
Canonical exit: 3 Apr 2023 (T+90)
64,000 shares@ US$2.4330.5% of flowCommon StockSEC:0001104659-20-045926:0
Canonical exit: 6 Jul 2020 (T+90)
112,200 sharesOrdinary SharesSEC:0001209191-20-018199:0
50,000 shares@ US$3.8944.4% of flowOrdinary SharesSEC:0001178913-18-003093:0
Canonical exit: 24 Feb 2019 (T+90)
50,000 shares@ US$3.9244.8% of flowOrdinary SharesSEC:0001178913-18-003093:1
Canonical exit: 25 Feb 2019 (T+90)
12,200 shares@ US$3.8810.8% of flowOrdinary SharesSEC:0001178913-18-003093:2
Canonical exit: 26 Feb 2019 (T+90)
8 of 8 declarations
